The changes in MLD and ALD from baseline to 24 months in the non-target lesions were significantly smaller in the rosuvastatin group than in the non-statin group ( -0.079 0.014 mm vs.-0 .135 0.019 mm , p = 0.022 ; -0.062 0.012 mmvs .